| P50 | author | Yujie Yuan | Q43373168 |
| P2093 | author name string | Jian Tu | |
| | Jin-Ning Ye | |
| | Shi-Rong Cai | |
| | Yu-Long He | |
| | Qing-Hai Li | |
| | Run Lin | |
| | Wei-Ling He | |
| | Ying-Zhao Wang | |
| | Chu-Wei Liu | |
| P2860 | cites work | Prognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature Review | Q24289005 |
| | Oncogenic ERBB3 mutations in human cancers | Q24293022 |
| | A quantitative protein interaction network for the ErbB receptors using protein microarrays | Q24293746 |
| | Identification of the Hepatocyte Growth Factor Receptor As the c- met Proto-Oncogene Product | Q24310794 |
| | Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer | Q24563539 |
| | Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab | Q24600031 |
| | Comprehensive molecular characterization of human colon and rectal cancer | Q24630415 |
| | A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor | Q24648517 |
| | EGF receptor trafficking: consequences for signaling and cancer | Q27021340 |
| | K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions | Q27680654 |
| | KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. | Q27824867 |
| | MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling | Q27851406 |
| | K-ras mutations and benefit from cetuximab in advanced colorectal cancer. | Q27851454 |
| | U3-1402, a Novel HER3-Targeting Antibody-Drug Conjugate, for the Treatment of Colorectal Cancer | Q92508053 |
| | Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial | Q93375221 |
| | ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. | Q40966152 |
| | A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS | Q41064400 |
| | Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer | Q41407101 |
| | Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy. | Q41410508 |
| | IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies. | Q41511106 |
| | Heterogeneity of receptor function in colon carcinoma cells determined by cross-talk between type I insulin-like growth factor receptor and epidermal growth factor receptor | Q41998867 |
| | Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial | Q42693879 |
| | A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer | Q42695640 |
| | Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma | Q42696314 |
| | Scatter factor is a fibroblast-derived modulator of epithelial cell mobility | Q42807925 |
| | All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired | Q42816057 |
| | Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan. | Q43184834 |
| | Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study | Q43765241 |
| | Treatment rationale and study design for a randomized, double-blind, placebo-controlled phase II study evaluating onartuzumab (MetMAb) in combination with bevacizumab plus mFOLFOX-6 in patients with previously untreated metastatic colorectal cancer | Q43840478 |
| | HER3 expression in patients with primary colorectal cancer and corresponding lymph node metastases related to clinical outcome | Q44029257 |
| | Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab. | Q44284095 |
| | Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT. | Q44526398 |
| | Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer. | Q44995693 |
| | Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung | Q45048643 |
| | Structural basis for inhibition of the epidermal growth factor receptor by cetuximab | Q45345151 |
| | Significance of mTOR signaling and its inhibitor against cancer stem-like cells in colorectal cancer | Q45778366 |
| | A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer | Q46091563 |
| | Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study | Q46465639 |
| | PTEN Regulates PI(3,4)P2 Signaling Downstream of Class I PI3K. | Q47100426 |
| | Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie). | Q47117539 |
| | Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA. | Q47143491 |
| | lncRNA MIR100HG-derived miR-100 and miR-125b mediate cetuximab resistance via Wnt/β-catenin signaling. | Q47648793 |
| | Association of Tumor HER3 Messenger RNA Expression With Panitumumab Efficacy in Advanced Colorectal Cancer | Q47707557 |
| | Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, an | Q48507379 |
| | The Genetic/Non-genetic Duality of Drug 'Resistance' in Cancer | Q49835177 |
| | Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer | Q50066241 |
| | Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer | Q27851456 |
| | PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies | Q27851465 |
| | Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. | Q27851711 |
| | A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer | Q27851787 |
| | HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients | Q27852057 |
| | The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis | Q27852988 |
| | Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis | Q27853129 |
| | HER2 activating mutations are targets for colorectal cancer treatment | Q27853193 |
| | Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer. | Q27853212 |
| | Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer | Q27853224 |
| | Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients With RAS Wild-Type Advanced Colorectal Cancer | Q27853335 |
| | Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial | Q27853380 |
| | MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer. | Q27853393 |
| | Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer | Q27860681 |
| | Mutations of the BRAF gene in human cancer | Q27860760 |
| | MicroRNAs: genomics, biogenesis, mechanism, and function | Q27861070 |
| | PTEN: life as a tumor suppressor | Q28203431 |
| | Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer | Q28240089 |
| | Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions | Q28257453 |
| | Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer | Q28298328 |
| | Insulin-like growth factors and their binding proteins: biological actions | Q28301853 |
| | ras oncogenes in human cancer: a review | Q29547769 |
| | Epigenetics in cancer | Q29547853 |
| | CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer | Q29614277 |
| | Ras oncogenes: split personalities | Q29615405 |
| | Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer | Q29616236 |
| | EGFR antagonists in cancer treatment | Q29616740 |
| | EGF-ERBB signalling: towards the systems level | Q29619032 |
| | Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status | Q29619648 |
| | Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial | Q29620127 |
| | The RAF proteins take centre stage | Q29620153 |
| | A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer | Q30316105 |
| | T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. | Q30832820 |
| | Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer | Q33391425 |
| | Multicenter phase II study of tivozanib (AV-951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancer | Q33407027 |
| | A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancer | Q33418329 |
| | Metastatic colorectal cancer: current state and future directions | Q38445676 |
| | K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study | Q38452428 |
| | Antroquinonol, a Ubiquinone Derivative from the Mushroom Antrodia camphorata, Inhibits Colon Cancer Stem Cell-like Properties: Insights into the Molecular Mechanism and Inhibitory Targets | Q38725272 |
| | FOXO3a and the MAPK p38 are activated by cetuximab to induce cell death and inhibit cell proliferation and their expression predicts cetuximab efficacy in colorectal cancer. | Q38743209 |
| | Global patterns and trends in colorectal cancer incidence and mortality. | Q38915351 |
| | Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer. | Q38916276 |
| | Association of MicroRNA-31-5p with Clinical Efficacy of Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer | Q38932418 |
| | Antroquinonol blocks Ras and Rho signaling via the inhibition of protein isoprenyltransferase activity in cancer cells | Q38948117 |
| | Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer. | Q39120801 |
| | Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer. | Q39703372 |
| | Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study | Q39821902 |
| | Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors. | Q40153403 |
| | Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines | Q40164557 |
| | Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells. | Q50616696 |
| | PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancer. | Q51028104 |
| | Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer. | Q52673332 |
| | A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors. | Q52873936 |
| | MET amplification, expression, and exon 14 mutations in colorectal adenocarcinoma. | Q54092400 |
| | First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors. | Q54240617 |
| | EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab. | Q54373171 |
| | MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors. | Q54383135 |
| | HER2 signaling and resistance to the anti-EGFR monoclonal antibody cetuximab: a further step toward personalized medicine for patients with colorectal cancer. | Q54510894 |
| | Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. | Q54962247 |
| | Insulin-like growth factors and cancer | Q56336667 |
| | Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study | Q56384328 |
| | Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation | Q56815463 |
| | Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS) | Q57908992 |
| | Requirement for intrinsic protein tyrosine kinase in the immediate and late actions of the EGF receptor | Q59054268 |
| | Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries | Q60142201 |
| | Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines | Q61808208 |
| | Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab | Q80704669 |
| | Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab | Q80704675 |
| | Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers | Q80765497 |
| | Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome | Q81897940 |
| | Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO C | Q84243064 |
| | Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer | Q88541726 |
| | Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer | Q89113396 |
| | HER2-targeted therapy: an emerging strategy in advanced colorectal cancer | Q90247451 |
| | Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer | Q90362927 |
| | The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients | Q90974072 |
| | The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity | Q91013772 |
| | MicroRNA-425-5p Expression Affects BRAF/RAS/MAPK Pathways In Colorectal Cancers | Q91046328 |
| | Adaptive mutability of colorectal cancers in response to targeted therapies | Q91172844 |
| | Trametinib in the treatment of multiple malignancies harboring MEK1 mutations | Q91246711 |
| | The current state of molecular testing in the treatment of patients with solid tumors, 2019 | Q92214210 |
| | Mechanisms of Receptor Tyrosine-Protein Kinase ErbB-3 (ERBB3) Action in Human Neoplasia | Q92224118 |
| | Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study | Q92280751 |
| | Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study | Q92502573 |
| | Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers | Q33888963 |
| | Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial | Q33922925 |
| | Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147 | Q33947880 |
| | Ras in cancer and developmental diseases | Q34202697 |
| | Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials | Q34263478 |
| | Epigenetic Alterations in Colorectal Cancer: Emerging Biomarkers | Q34487177 |
| | HGF rescues colorectal cancer cells from EGFR inhibition via MET activation | Q34550898 |
| | Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. | Q34554584 |
| | Lack of correlation between epidermal growth factor receptor status and response to Panitumumab monotherapy in metastatic colorectal cancer | Q34618161 |
| | Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. | Q34624122 |
| | Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen | Q34642136 |
| | Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine | Q35067570 |
| | Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing. | Q35133788 |
| | Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer | Q35212113 |
| | The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab. | Q35584314 |
| | MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1. | Q35672735 |
| | EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib | Q35841043 |
| | Does overexpression of HER-2 correlate with clinicopathological characteristics and prognosis in colorectal cancer? Evidence from a meta-analysis | Q35957036 |
| | Epigenetics and colorectal cancer | Q36081553 |
| | Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancer | Q36450457 |
| | DNA methylation status as a biomarker of anti-epidermal growth factor receptor treatment for metastatic colorectal cancer | Q36467389 |
| | The genomic landscape of response to EGFR blockade in colorectal cancer. | Q36930106 |
| | Targeting the epidermal growth factor receptor in metastatic colorectal cancer | Q37002166 |
| | Deficient mismatch repair system in patients with sporadic advanced colorectal cancer | Q37081098 |
| | TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy | Q37177918 |
| | Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer | Q37274280 |
| | A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy | Q37352435 |
| | MET signalling: principles and functions in development, organ regeneration and cancer | Q37811895 |
| | Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials | Q37975484 |
| | The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials | Q38074290 |
| | Treatment related severe and fatal adverse events with cetuximab in colorectal cancer patients: a meta-analysis | Q38115675 |
| | BRAF mutation is associated with distinct clinicopathological characteristics in colorectal cancer: a systematic review and meta-analysis | Q38151250 |
| | Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution | Q38257912 |
| | Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer. | Q38377594 |
| | Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab | Q38420145 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 3 | |
| P921 | main subject | metastatic colon cancer | Q108566365 |
| P304 | page(s) | 179-191 | |
| P577 | publication date | 2020-06-23 | |
| P1433 | published in | Gastroenterology report | Q27725210 |
| P1476 | title | Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance | |
| P478 | volume | 8 | |